Danaher Corporation (DHR) Quote

DHR Rocks ...

Just realized the div cut was because of the Veralto spinoff last October. So no big deal.

"Danaher Cuts Quarterly Dividend to 24 Cents"

Danaher lowered its quarterly cash dividend to 24 cents a share from 27 cents.
The new payout, equal to 96 cents a year, represents an annual yield of 0.4% based on Tuesday's closing price of $219.44.
The health-care and laboratory-supply company said the dividend is payable on Jan. 26, 2024, to shareholders of record on Dec. 29.

https://www.marketscreener.com/quote/stock/DANAHER-CORPORATION-12295/news/Danaher-Cuts-Quarterly-Dividend-to-24-Cents-45507051/

Danaher Corp Quarterly Dividends

Date Dividends
Jun 29, 2023 0.27 Dividend
Mar 30, 2023 0.27 Dividend
Dec 29, 2022 0.25 Dividend
Sep 29, 2022 0.25 Dividend
Jun 23, 2022 0.25 Dividend
Mar 24, 2022 0.25 Dividend
Dec 29, 2021 0.21 Dividend
Sep 29, 2021 0.21 Dividend
Jun 24, 2021 0.21 Dividend
Mar 25, 2021 0.21 Dividend
Dec 24, 2020 0.18 Dividend
Sep 25, 2020 0.18 Dividend
Jun 25, 2020 0.18 Dividend
Mar 26, 2020 0.18 Dividend
Dec 26, 2019 0.17 Dividend
Sep 26, 2019 0.17 Dividend
Jun 27, 2019 0.17 Dividend
Mar 28, 2019 0.17 Dividend
Dec 27, 2018 0.16 Dividend
Sep 27, 2018 0.16 Dividend

"Danaher ups dividend by 8% to $0.27"

"Danaher (NYSE:DHR) declares $0.27/share quarterly dividend, 8% increase from prior dividend of $0.25.
Forward yield 0.43%
Payable April 28; for shareholders of record March 31; ex-div March 30, 2023."

https://seekingalpha.com/news/3939480-danaher-corporation-declares-0_27-dividend

"Danaher Stock Is Soaring. Earnings Surged on Covid-Test Success."

"Danaher DHR +7.93% produced strongly upside second-quarter results, and shares are up a lot in early Thursday trading. The company’s Covid-testing business was an unexpected surprise."

https://www.barrons.com/articles/danaher-earnings-stock-covid-51658420631

Substantial Div Increase for Danaher

Date Dividends
Mar 24, 2022 0.25 Dividend
Dec 29, 2021 0.21 Dividend
Sep 29, 2021 0.21 Dividend
Jun 24, 2021 0.21 Dividend
Mar 25, 2021 0.21 Dividend
Dec 24, 2020 0.18 Dividend
Sep 25, 2020 0.18 Dividend
Jun 25, 2020 0.18 Dividend
Mar 26, 2020 0.18 Dividend
Dec 26, 2019 0.17 Dividend
Sep 26, 2019 0.17 Dividend
Jun 27, 2019 0.17 Dividend
Mar 28, 2019 0.17 Dividend
Dec 27, 2018 0.16 Dividend
Sep 27, 2018 0.16 Dividend
Jun 28, 2018 0.16 Dividend
Mar 28, 2018 0.16 Dividend
Dec 28, 2017 0.14 Dividend

Thanks for those links. Recent advancements in generator technology are interesting. Over the years, especially when storms make headlines, I've thought about getting a generator for my home. But they're costly and need fueling and maintenance. One more thing to worry about. Where I live significant outages are rare.

Wow, Danaher hitting $325.

Bar, Danaher has always been a great long term stock, though the Covid related aspect has moved it into the 'momentum play' realm. Earnings growth of 92%, rev growth 36%, PE 43 (per Yahoo), this likely won't be sustainable forever for a company the size of Danaher, although the high growth and valuation may continue for some time. A great long term stock but high valuation.

Generac is even pricier, but 1/10 the size and should keep growing for many years. Even with the recent class action lawsuits, the stock is back near the highs again. They also have the energy storage and smart grid aspects -


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164787724

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164485279

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165681364


These are both great stocks. The market needs a decent pullback, but the Fed 'juice' has prevented even a 5% correction. So I'm mostly on the sidelines for now. I would prefer a buy/hold forever strategy like you have, but am increasingly averse to capital loss, so currently overweight in cash, T-Bills, and shorter term bonds.

Generac, with a market cap of $28 billion, joined the S&P 500 a few months ago, I see. Previously it was one of the largest firms in the S&P Midcap 400 index.

Generac top #7 holding be weight for SPX pure growth ETF. The other day was just looking over what constitutes pure growth vs pure value investments and noticed Generac was on there.

Interesting. Because of the hurricane I was just reviewing your Generac which I always considered to be a sensible speculation. Before Generac rose so much in the past couple of years, it was too small for my taste and it paid no dividend. I figured it didn't have much of a moat as many firms around the world make or could make generators.

I don't add many new stocks, relying mostly on index funds. Danaher is my most recent addition, from several years ago and it's certainly a honey of an investment.

Hi Bar, OT - >> General Stock Ideas <<

I-Hub converted it into a 'Premium' board after an extended heated argument over the Covid vaccines (a touchy topic these days). I was not the official moderator on that board, so was unable to effectively police the board. So I think the idea was to basically shut down activity on that board by making it 'Premium'.

Anyway, I moved over to the 'Awesome Stocks' board (link below), and am trying to keep things civil. You are welcome to post anytime :o) -


https://investorshub.advfn.com/Awesome-Stocks-36107/

Is your main General Stock Ideas board for IHUB subscribers only now? Did you mean to make that change?

$324 DHR wow

>>> Is Danaher a Buy in a Post-Pandemic World?

Analyzing the investment case for buying stock in the high-flying life sciences and diagnostics company.


Motley Fool

by Lee Samaha

Aug 4, 2021


https://www.fool.com/investing/2021/08/04/is-danaher-a-buy-in-a-post-pandemic-world/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article


Key Points

The pandemic has enhanced the company's long-term growth potential.

Current trading continues to exceed expectations.

Non-COVID-19 related revenue is back in growth mode.


Life science and diagnostics company Danaher (NYSE:DHR) is one of the big winners from the COVID-19 pandemic. Its diagnostic tests help detect the coronavirus, and its life sciences tools help medical bodies research and develop vaccines and therapies for it.

That said, what happens to the company's growth rate after the pandemic is over? Are investors in the stock about to be left holding a stock trading on a high valuation that's just about to see earnings growth prospects deteriorate?

Three reasons Danaher can keep on delivering

I think there's reason to believe that Danaher can keep growing at a very healthy clip, even in a post-pandemic environment.

Current earnings momentum is robust across all its businesses, COVID-19 related and non-COVID-19 alike.

Management's guidance for non-COVID-19 related revenue growth in 2021 has been upgraded and demonstrates underlying strength in the business.
The pandemic has strengthened the company's core business and growth prospects.

Strong earnings momentum

The company recently delivered its second-quarter earnings, and it managed to sail past management's previous guidance. For example, management had previously forecast second-quarter core revenue growth would come in within the mid-20% range, but it came in at 31.5%. As such, management upgraded its expectation for full-year core revenue growth from "high teens" to "approximately 20%."

As you can see below, the life sciences and diagnostics segments continue a powerful run, boosted by the pandemic (more on that in a moment), and the environmental and applied solutions (EAS) business is also back in growth mode. For reference, life sciences contributed $2.3 billion of operating profit in the first half compared to $1.3 billion from diagnostics and $565 million from EAS.

EAS is a collection of water quality and product ID businesses. During the earnings call, CEO Rainer Blair noted that both business platforms grew strongly in the quarter as the reopening of the economy increased sales and order rates as customers were investing in "larger projects" again.

Non-COVID-19 growth is strong too

The burning question on everybody's lips is, what kind of growth rate can investors expect after the pandemic? To help answer it, Danaher's management breaks out its guidance into COVID-19 related revenue and its "base business." As noted earlier, the full-year core revenue growth guidance was raised to "approximately 20%."

Going into more detail on the matter, Blair said "We anticipate that COVID related revenue tailwinds will be an approximately 10% contribution to the core revenue growth rate, and in our base business, we now expect that core revenue will be up 10% for the full year, an increase from our prior expectation of high single-digit."

In other words, the ramp up in the guidance primarily comes down to an increase in the guidance from the base business. That bodes well for Danaher's post-pandemic growth prospects.

The pandemic has structurally enhanced Danaher's growth

This is a subtle and critical point to understand. It's not just that the pandemic provided a temporary boost to Danaher's prospects. In life sciences, the investment made worldwide in vaccine and therapeutic science to combat the coronavirus is likely to spill out into broader-based research that can benefit Danaher for years to come.

Meanwhile, Blair outlined that monoclonal antibody-based therapies in development have increased 50% "from just five years ago." Turning back to COVID-19, there's always the possibility that a third booster shot and wide-scale vaccination of children will provide a near-term boost to Danaher's sales.

Danaher has increased its installed base of diagnostic platforms by over 40% since the pandemic started. That's important because the diagnostics business works based on the "razor/razor blade" business model. In other words, more platform sales lead to more opportunities for Danaher to sell new tests into the installed base. For example, Blair pointed out that assays (tests) for sexual health and hospital-acquired infections were up 30% in the second quarter. Also, Danaher is continually working on new assays.

Danaher is ramping up capital spending from $790 million in 2020 to around $1.5 billion in 2021, partly to build on the growth in assay development and fuel growth in the Cytiva biopharma business bought from General Electric in 2020.

Is Danaher a buy?

The exciting thing about Danaher's valuation is that it trades on roughly the same enterprise value (market cap plus net debt)-to-earnings before interest, taxation, depreciation, and amortization (EBITDA) valuation as it did before the pandemic started.

Therefore, if you believe in relative valuations, then Danaher is an attractive stock because the pandemic has enhanced its long-term growth potential. On the other hand, it's still a pretty hefty valuation to trade on, and cautious investors might want to wait for a dip to buy into a very attractive company.

<<<

I will definitely find those other 17 and add them to my portfolio just like DHR, one by one. Eventually will get them all. I trust your success.

The penny junk is entertainment to get me through the daily 9-6 at the office. You win some. You lose some.

DHR touched another high. Amazing performance.

Have a good weekend.

That's a scary thought. Who did you follow into all your crumbling penny stocks?

At least you're improving. DHR is a blue chip with a market cap of $220 billion. Be aware that I only buy blue chips and I have a profit in every one of the ~17 individual stocks I own. Of course my average holding period can be measured in decades.

I make money with my stocks.

I followed you to find this stock. Impressive indeed. Thank you. Will accumulate when possible.

Danaher. Very impressive. Just touched another record high.

312.70 this hits new highs every day. Is this normal?

Danaher 10-year Chart

DHR Split History
Date Ratio
01/23/1995 2 for 1
06/01/1998 2 for 1
05/21/2004 2 for 1
06/14/2010 2 for 1
07/05/2016 1319 for 1000

Forward split please, soon.

Bought more.

Bought in today for long term hold. Solid stock here. DHR

$254. Another record high for DHR

DHR— So nice they surpassed estimates yay!! Thanks!

"Danaher (NYSE-DHR) Q1 Earnings and Revenues Surpass Estimates"

"Danaher (DHR) came out with quarterly earnings of $2.52 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 50.90%. A quarter ago, it was expected that this industrial and medical device maker would post earnings of $1.84 per share when it actually produced earnings of $2.08, delivering a surprise of 13.04%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times."

https://finance.yahoo.com/news/danaher-dhr-q1-earnings-revenues-113011852.html

This is interesting in light of recent price action.

https://www.quantiumresearch.co.uk/post/potential-double-top-formation-for-danaher-corp

Danaher Significant Payout Increase.

"DHR designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates in the Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions segments. DHR was founded in 1969 and is headquartered in Washington, the District of Columbia.

On Feb 23, DHR declared a quarterly dividend of 21¢ per share.
This is an increase of 16.67% from the prior dividend of 18¢.
Payable Apr 30, to shareholders of record on Mar 26; ex-div: Mar 25."

https://seekingalpha.com/article/4410154-dividend-increases-february-20minus-26-2021

Thanks for the info about hedge funds owning it. I see that it isn’t cheap. Thanks for the great info! Will consider it! Enjoy a great day and stay warm!

At 50X trailing earnings, DHR isn't cheap. I've noticed it's currently one of the most heavily owned stocks by hedge funds. This list has DHR at eighth.
https://wallethub.com/edu/hedge-fund-stocks/38113

Aside from index funds, I never recommend specific stocks, even NYSE quality issues like DHR. I'll leave that to IHUB's army of shills.

GL

DHR— Nice high!

I don’t own it right now —but will consider buying some! Thank you much!

Just noticed DHR touching record high, ~$247. Do you own it?

Love it! Steady price rise and divi increase!! Cannot beat that!!

@@@@ Loving my Apple stock too —-and all the forward splits!! Have quite a few shares now and it’s my second best performer in the Portfolio—after Microsoft!! Cheers!!

$246. Steady price rise and div increase due in late March.

$236 VERY NICE!! Thanks!

DHR 5-Year Q Div History, and spinoff
Date Dividends
Sep 25, 2020 0.18 Dividend
Jun 25, 2020 0.18 Dividend
Mar 26, 2020 0.18 Dividend
Dec 26, 2019 0.17 Dividend
Sep 26, 2019 0.17 Dividend
Jun 27, 2019 0.17 Dividend
Mar 28, 2019 0.17 Dividend
Dec 27, 2018 0.16 Dividend
Sep 27, 2018 0.16 Dividend
Jun 28, 2018 0.16 Dividend
Mar 28, 2018 0.16 Dividend
Dec 28, 2017 0.14 Dividend
Sep 28, 2017 0.14 Dividend
Jun 28, 2017 0.14 Dividend
Mar 29, 2017 0.14 Dividend
Dec 28, 2016 0.125 Dividend
Sep 28, 2016 0.125 Dividend
Jul 05, 2016 24.56 Dividend spinoff of Fortive stock
Jun 01, 2016 0.16 Dividend
Mar 23, 2016 0.16 Dividend
Mar 22, 2016 0.16 Dividend
Dec 17, 2015 0.135 Dividend

WASHINGTON, June 1, 2016 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today declared a pro rata dividend of all of the common stock of Fortive Corporation to Danaher stockholders of record as of the close of business on June 15, 2016 (the "Record Date"). The dividend is payable on July 2, 2016 ("Distribution Date") in connection with the previously announced separation of Danaher's existing Test & Measurement segment, Industrial Technologies segment (excluding the Product Identification platform) and Retail/Commercial Petroleum platform through the planned spin-off of Fortive. As a result of the dividend, Danaher stockholders will receive one share of Fortive common stock for every two shares of Danaher common stock they hold on the Record Date

DHR keeps hitting record highs, $236.

DHR— Thanks for that great info Bar1080!! Appreciated!

Enjoy a great weekend!!

Amazing the fast/accurate CV tests arriving from established medical research firms and universities. Danaher Corp (NYSE: DHR) announced that its Beckman division has developed a dirt cheap test that boasts 98.3% sensitivity (correctly identifying true positives) and 99.9% specificity (correctly identifying true negatives). Results in 15 minutes.

DHR is among about 19 soaring blue chips I HOLD.

https://seekingalpha.com/news/3621076-fda-oks-emergency-use-of-new-beckman-coronavirus-antibody-test

Earnings news.

Damn, any news? I hold a pretty big chunk of DHR but haven't paid attention to it lately.

201.50

This is going 200+

New all-time high for DHR at $180.

Hello, new to board. I think the billion or so $ will be used in part to create several new ROBAL (reagents on board) Perhaps four new lines. How else will meet the demand projected during CC.

What's the link between Aria and Danaher?

Do you realize how big Danaher is? $100+ billion market cap. OTOH DHR has been one of the best performing stocks lately.

Here's some info about the Aria test in NY:
https://www.cnbc.com/2020/04/14/coronavirus-new-york-city-will-buy-100000-test-kits-per-week-from-mix-of-local-and-indiana-contractors.html

Anyone estimate how significant the Aria diagnostic with its huge agreement to send the covid testing to NY state will be on DHR bottom line? I'm basing this on the conference call that mayor deblasio said about Aria and i see Dahaher owns them